Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Stock

Showing results (101-110 of 322) with videos related to

Pageof 33
Sort By:
Leukemia & Lymphoma|September 6, 2007
Successful allogeneic transplantation of patients with suspected prior invasive mold infectionBrian T Hill, Lavayna Kondapalli, Andrew Artz, et al.
Cancer Chemotherapy and Pharmacology|August 2, 2008
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804Richard M Stone, Kathleen A Donohue, Wendy Stock, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 16, 2006
Gene expression changes associated with progression and response in chronic myeloid leukemiaJerald P Radich, Hongyue Dai, Mao Mao, et al.
Leukemia & Lymphoma|December 25, 2015
Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessmentChristopher R D'Angelo, Masha Kocherginsky, Jennifer Pisano, et al.
Ejhaem|January 27, 2025
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemiaRafael Madero-Marroquin, Ryan W Hunter, Caner Saygin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2008
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantationAndrew S Artz, Amittha Wickrema, Shira Dinner, et al.
Leukemia Research|August 7, 2010
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902Richard M Stone, Barry Moser, Ben Sanford, et al.
Cytotherapy|May 3, 2012
Influence of related donor age on outcomes after peripheral blood stem cell transplantationElie M Richa, Rangesh Kunnavakkam, Lucy A Godley, et al.
Leukemia & Lymphoma|December 15, 2010
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapseVaishalee P Kenkre, Sarah Horowitz, Andrew S Artz, et al.
Haematologica|November 22, 2011
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909Hongtao Liu, Jeffrey L Johnson, Greg Koval, et al.
Pageof 33

Showing results (101-110 of 322) with videos related to

Sort By:
Pageof 33
Leukemia & Lymphoma|September 6, 2007
Successful allogeneic transplantation of patients with suspected prior invasive mold infectionBrian T Hill, Lavayna Kondapalli, Andrew Artz, et al.
Cancer Chemotherapy and Pharmacology|August 2, 2008
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804Richard M Stone, Kathleen A Donohue, Wendy Stock, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 16, 2006
Gene expression changes associated with progression and response in chronic myeloid leukemiaJerald P Radich, Hongyue Dai, Mao Mao, et al.
Leukemia & Lymphoma|December 25, 2015
Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessmentChristopher R D'Angelo, Masha Kocherginsky, Jennifer Pisano, et al.
Ejhaem|January 27, 2025
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemiaRafael Madero-Marroquin, Ryan W Hunter, Caner Saygin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2008
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantationAndrew S Artz, Amittha Wickrema, Shira Dinner, et al.
Leukemia Research|August 7, 2010
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902Richard M Stone, Barry Moser, Ben Sanford, et al.
Cytotherapy|May 3, 2012
Influence of related donor age on outcomes after peripheral blood stem cell transplantationElie M Richa, Rangesh Kunnavakkam, Lucy A Godley, et al.
Leukemia & Lymphoma|December 15, 2010
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapseVaishalee P Kenkre, Sarah Horowitz, Andrew S Artz, et al.
Haematologica|November 22, 2011
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909Hongtao Liu, Jeffrey L Johnson, Greg Koval, et al.
Pageof 33